Akut szívizom-infarctusban végzett elso magyar autológ csontveloi ossejt transzplantációk során szerzett tapasztalataink

Márton Vértesljai, Zsolt Piróth, Géza Fontos, Attila Tóth, T. Símor, Sándor Lueff, Péter Reményi, Marienn Réti, T. Masszi, P. Andréka

Research output: Article

1 Citation (Scopus)

Abstract

Intracoronary transfer of autologous bone marrow cells promotes recovery of left ventricular systolic function in patients with acute myocardial infarction. Although the exact mechanisms of stem cell therapy are still intensely debated, the concept of stem cell therapy has already been introduced into the clinical practice - at least as an adjunctive therapy in clinical trials. In this article the authors report their experiences about the first Hungarian phase I. trial in bone marrow stem cell transplantation after acute myocardial infarction. So far, four patients with acute ST elevation myocardial infarction were eligibile and recruited into the trial. All patients received purified, autologous bone marrow stem cells into the re-opened infarct related artery via a second catheterisation. The primary end point of the study is ejection fraction, which is measured by cardiac MRI at the beginning and 6 months after recruitment. So far, cell transfer did not increase the risk of adverse clinical events or proarrhythmic effects.

Original languageHungarian
Pages (from-to)3-6
Number of pages4
JournalOrvosi Hetilap
Volume147
Issue number1
Publication statusPublished - jan. 8 2006

Fingerprint

Bone Marrow Transplantation
Stem Cells
Myocardial Infarction
Cell- and Tissue-Based Therapy
Bone Marrow Cells
Stem Cell Transplantation
Left Ventricular Function
Catheterization
Arteries
Clinical Trials
Therapeutics

Keywords

  • Myocardial infarction
  • Myocardial regeneration
  • Stem cell therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Akut szívizom-infarctusban végzett elso magyar autológ csontveloi ossejt transzplantációk során szerzett tapasztalataink. / Vértesljai, Márton; Piróth, Zsolt; Fontos, Géza; Tóth, Attila; Símor, T.; Lueff, Sándor; Reményi, Péter; Réti, Marienn; Masszi, T.; Andréka, P.

In: Orvosi Hetilap, Vol. 147, No. 1, 08.01.2006, p. 3-6.

Research output: Article

Vértesljai, M, Piróth, Z, Fontos, G, Tóth, A, Símor, T, Lueff, S, Reményi, P, Réti, M, Masszi, T & Andréka, P 2006, 'Akut szívizom-infarctusban végzett elso magyar autológ csontveloi ossejt transzplantációk során szerzett tapasztalataink', Orvosi Hetilap, vol. 147, no. 1, pp. 3-6.
Vértesljai, Márton ; Piróth, Zsolt ; Fontos, Géza ; Tóth, Attila ; Símor, T. ; Lueff, Sándor ; Reményi, Péter ; Réti, Marienn ; Masszi, T. ; Andréka, P. / Akut szívizom-infarctusban végzett elso magyar autológ csontveloi ossejt transzplantációk során szerzett tapasztalataink. In: Orvosi Hetilap. 2006 ; Vol. 147, No. 1. pp. 3-6.
@article{b602835f391a40f391126fd5b69b7066,
title = "Akut sz{\'i}vizom-infarctusban v{\'e}gzett elso magyar autol{\'o}g csontveloi ossejt transzplant{\'a}ci{\'o}k sor{\'a}n szerzett tapasztalataink",
abstract = "Intracoronary transfer of autologous bone marrow cells promotes recovery of left ventricular systolic function in patients with acute myocardial infarction. Although the exact mechanisms of stem cell therapy are still intensely debated, the concept of stem cell therapy has already been introduced into the clinical practice - at least as an adjunctive therapy in clinical trials. In this article the authors report their experiences about the first Hungarian phase I. trial in bone marrow stem cell transplantation after acute myocardial infarction. So far, four patients with acute ST elevation myocardial infarction were eligibile and recruited into the trial. All patients received purified, autologous bone marrow stem cells into the re-opened infarct related artery via a second catheterisation. The primary end point of the study is ejection fraction, which is measured by cardiac MRI at the beginning and 6 months after recruitment. So far, cell transfer did not increase the risk of adverse clinical events or proarrhythmic effects.",
keywords = "Myocardial infarction, Myocardial regeneration, Stem cell therapy",
author = "M{\'a}rton V{\'e}rtesljai and Zsolt Pir{\'o}th and G{\'e}za Fontos and Attila T{\'o}th and T. S{\'i}mor and S{\'a}ndor Lueff and P{\'e}ter Rem{\'e}nyi and Marienn R{\'e}ti and T. Masszi and P. Andr{\'e}ka",
year = "2006",
month = "1",
day = "8",
language = "Hungarian",
volume = "147",
pages = "3--6",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Akut szívizom-infarctusban végzett elso magyar autológ csontveloi ossejt transzplantációk során szerzett tapasztalataink

AU - Vértesljai, Márton

AU - Piróth, Zsolt

AU - Fontos, Géza

AU - Tóth, Attila

AU - Símor, T.

AU - Lueff, Sándor

AU - Reményi, Péter

AU - Réti, Marienn

AU - Masszi, T.

AU - Andréka, P.

PY - 2006/1/8

Y1 - 2006/1/8

N2 - Intracoronary transfer of autologous bone marrow cells promotes recovery of left ventricular systolic function in patients with acute myocardial infarction. Although the exact mechanisms of stem cell therapy are still intensely debated, the concept of stem cell therapy has already been introduced into the clinical practice - at least as an adjunctive therapy in clinical trials. In this article the authors report their experiences about the first Hungarian phase I. trial in bone marrow stem cell transplantation after acute myocardial infarction. So far, four patients with acute ST elevation myocardial infarction were eligibile and recruited into the trial. All patients received purified, autologous bone marrow stem cells into the re-opened infarct related artery via a second catheterisation. The primary end point of the study is ejection fraction, which is measured by cardiac MRI at the beginning and 6 months after recruitment. So far, cell transfer did not increase the risk of adverse clinical events or proarrhythmic effects.

AB - Intracoronary transfer of autologous bone marrow cells promotes recovery of left ventricular systolic function in patients with acute myocardial infarction. Although the exact mechanisms of stem cell therapy are still intensely debated, the concept of stem cell therapy has already been introduced into the clinical practice - at least as an adjunctive therapy in clinical trials. In this article the authors report their experiences about the first Hungarian phase I. trial in bone marrow stem cell transplantation after acute myocardial infarction. So far, four patients with acute ST elevation myocardial infarction were eligibile and recruited into the trial. All patients received purified, autologous bone marrow stem cells into the re-opened infarct related artery via a second catheterisation. The primary end point of the study is ejection fraction, which is measured by cardiac MRI at the beginning and 6 months after recruitment. So far, cell transfer did not increase the risk of adverse clinical events or proarrhythmic effects.

KW - Myocardial infarction

KW - Myocardial regeneration

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=33645919608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645919608&partnerID=8YFLogxK

M3 - Article

C2 - 16519064

AN - SCOPUS:33645919608

VL - 147

SP - 3

EP - 6

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 1

ER -